Apotex Corporation, a US-based company involved in generic pharmaceuticals and biosimilars, announced on Tuesday that it has introduced Teriparatide Injection, a single-patient-use pre-filled pen intended for the treatment of osteoporosis, in the US.
Teriparatide Injection is supplied as a single-patient-use pre-filled pen containing 250 mcg/mL, capable of administering 28 daily doses of 20 mcg per pen.
Michael Bohling, Apotex Corp vice president of Sales and Marketing, said: "Osteoporosis impacts approximately 10 million Americans, and millions more have low bone density, placing them at high risk. The launch of this product will provide much-needed affordable access for these patients."
Kiran Krishnan, PhD, Apotex Corp senior vice president of Global Regulatory Affairs, also commented: "The approval of Teriparatide Injection is a testament to Apotex's commitment to the development of complex generic drugs and ensures expanded access for patients to affordable, high-quality medicines."
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical